natgillin/translations-raw huggingface dataset:
AUC 4.76 (4.07, 5.56)
Interakcija se ispitivala s
AUC 7.50 (5.92, 9.51)
AUC 7,50 (5,92; 9,51)
AUC 7.88 (6.82-9.07)
AUC 7,88 (6,82-9,07)
AUC 70.3 (52.9-93.4)**
AUC 70,3 (52,9-93,4)
AUC 8.35 (7.38, 9.45)
AUC 8,35 (7,38; 9,45)
AUC 8.96 (7.75-10.35)
AUC 8,96 (7,75-10,35)
AUC : 0 31% (0 8 to 0 47)
AUC: ↓ 31% (↓ 8 do ↓ 47)
AUC : ↑ 3-fold
AUC: ↑ 22
AUC = area under the curve; Cmax = maximum plasma concentration; IU = International Unit; MRT = mean residence time; N = number of subjects; SD = standard deviation; tmax = time to maximum concentration occurs; Vss = volume of distribution at steady state; VWF:Ag = von Willebrand factor: Antigen; VWF:CB = von Willebrand factor: Collagen Binding; VWF:RCo = von Willebrand factor: Ristocetin Cofactor, FVIII:C = Factor VIII: Coagulant
AUC = površina ispod krivulje; Cmax = maksimalna koncentracija u plazmi; IU = međunarodna jedinica; MRT = srednje vrijeme zadržavanja; N = broj ispitanika; SD = standardna devijacija; tmax = vrijeme do postizanja maksimalne koncentracije; Vss = volumen distribucije u stanju dinamičke ravnoteže; VWF:Ag = Von Willebrandov factor: Antigen; VWF:CB = Von Willebrandov factor: kolagen vezajući; VWF:RCo = Von Willebrandov factor: Ristocetin kofaktor; FVIII:C= faktor VIII:koagulans
AUC and Cmax ↓ ~50%
Cmax: ↓ 50
AUC can result in virological
može dovesti do neuspješnog
AUC change from baseline in pupil diameter (mm) during surgery (Co-primary endpoint) [Mean(SD)]
Promjena AUC-a od početne vrijednosti u promjeru zjenice (mm) tijekom kirurškog zahvata (koprimarni ishod) [srednja vrijednost (SD)]
AUC change from baseline in pupil diameter (mm) during surgery (Co-primary endpoint) [MeanSD)]
Promjena AUC-a od početne vrijednosti u promjeru zjenice (mm) tijekom kirurškog zahvata (koprimarni ishod) [srednja vrijednost (SD)]
AUC in cervicovaginal fluid, cervical tissue and vaginal tissue were 6-10% of those in corresponding plasma at steady state.
AUC u cervikovaginalnoj tekućini, cervikalnom tkivu i vaginalnom tkivu iznosio je 6-10% odgovarajuće vrijednosti u plazmi u stanju dinamičke ravnoteže.
AUC over the 24-h dosing interval on Day 14 compared to Day 1, was in the range of 2.9 to 3.5 for once-daily inhaled doses between 150 microgram and 600 microgram.
AUC tijekom 24-satnog razdoblja doziranja 14. dana u usporedbi s 1. danom bio je u rasponu od 2,9 do 3,5 za doze od 150 mikrograma do 600 mikrograma inhalirane jedanput na dan.
AUC over the 24-h dosing interval on day 14 or day 15 compared to day 1, was in the range of 2.9 to 3.8 for once-daily inhaled doses between 60 µg and 480 µg (delivered dose).
AUC tijekom 24- satnog razdoblja doziranja 14. dana ili 15. dana u usporedbi s 1. danom bio je u rasponu od 2.9 do 3.8 za doze između 60 µg i 480 µg (isporučena doza) inhalirane jedanput na dan.
AUC values increased approximately linearly while Cmax increased slightly less than linearly with increasing dose-rates over the intended therapeutic dose range.
PIK (površina ispod krivulje) je narasla uglavnom linearno dok je Cmax s povećanim rasponima doza u odnosu na namjeravani terapijski raspon doze porastao nešto manje nego linearno.
AUC ↑ 1.10 (0.94-1.28)
AUC ↑ 1,10 (0,94-1,28)
AUC ↑ 1.10 (0.94-1.28)
AUC ↑ 1,22 (1,13-1,31)
AUC ↑ 1.14 (0.88-1.47)
AUC ↑ 1,14 (0,88-1,47)
AUC ↑ 1.18 (0.90-1.56)
AUC ↑ 1,18 (0,90-1,56)
AUC ↑ 1.18 (1.03-1.36)
AUC ↑ 1,18 (1,03-1,36)
AUC ↑ 1.22 (1.13-1.31)
AUC ↑ 1,22 (1,13-1,31)
AUC ↑ 1.27 (1.19-1.36)
AUC ↑ 1,10 (0,94-1,28)
AUC ↑ 1.27 (1.19-1.36)
AUC ↑ 1,27 (1,19-1,36)
AUC ↑ 1.30 (1.18-1.44)
AUC ↑ 1,30 (1,18-1,44)
AUC ↑ 1.36 (1.25-1.47)
AUC ↑ 1,36 (1,25-1,47)
AUC ↑ 1.41 (1.22-1.62)
AUC ↑ 1,41 (1,22-1,62)
AUC ↑ 1.41 (1.22-1.62)
AUC ↓ 0,86 (0,76-0,97)
AUC ↑ 1.42 (1.34-1.50)
AUC ↑ 1,42 (1,34-1,50)
AUC ↑ 1.69 (1.53-1.86)
AUC ↑ 1,69 (1,53-1,86)
AUC ↑ 1.86 (1.73-2.00)
AUC ↑ 1,86 (1,73-2,00)
AUC ↑ 3.10 (2.57-3.74)
AUC ↑ 3,10 (2,57-3,74)
AUC ↑119% (↑78% ↑169%).
dezacetil-rifabutina ↑119% (↑78
AUC ↓ 0.24 (0.18-0.33)
AUC ↓ 0,24 (0,18-0,33)
AUC ↓ 0.29 (0.26-0.34)
AUC ↓ 0,29 (0,26-0,34)
AUC ↓ 0.43 (0.36-0.51)
AUC ↓ 0,43 (0,36-0,51)
AUC ↓ 0.43 (0.36-0.51)
HMG Co-A reduktaze može
AUC ↓ 0.47 (0.38-0.58)
AUC ↓ 0,47 (0,38-0,58)
AUC ↓ 0.61 (0.53-0.69)
AUC ↓ 0,61 (0,53-0,69)
AUC ↓ 0.62 (0.48-0.80)
AUC ↓ 0,62 (0,48-0,80)
AUC ↓ 0.63 (0.54-0.73)
AUC ↓ 0,63 (0,54-0,73)
AUC ↓ 0.63 (0.54-0.74)
AUC ↓ 0,63 (0,54-0,74)
AUC ↓ 0.63 (0.54-0.74)
AUC ↓ 0,83 (0,75-0,94)
AUC ↓ 0.65 (0.59-0.71)
AUC ↓ 0,65 (0,59-0,71)
AUC ↓ 0.67 (0.56-0.80)
AUC ↓ 0,67 (0,56-0,80)
AUC ↓ 0.77 (0.66-0.91)
AUC ↓ 0,77 (0,66-0,91)
AUC ↓ 0.81 (0.75-0.88)
AUC ↓ 0,81 (0,75-0,88)
AUC ↓ 0.83 (0.74-0.92)
AUC ↓ 0,83 (0,74-0,92)
AUC ↓ 0.83 (0.75-0.94)
AUC ↓ 0,83 (0,75-0,94)
AUC ↓ 0.83 (0.75-0.94)
manjenje izloženosti etravirinu, a može se
AUC ↓ 0.86 (0.76-0.97)
AUC ↓ 0,63 (0,58-0,68)
AUC ↓ 0.86 (0.76-0.97)
AUC ↓ 0,86 (0,76-0,97)
AUC ↓ 0.86 (0.79-0.93)
AUC ↓ 0,86 (0,79-0,93)
AUC ↓ 0.87 (0.77-0.98)
AUC ↓ 0,87 (0,77-0,98)
AUC ↓ 0.90 (0.68-1.18)
AUC ↓ 0,90 (0,68-1,18)
AUC ↔ 0.89 (0.82-0.96)
AUC ↔ 0,89 (0,82-0,96)
AUC ↔ 0.89 (0.82-0.96)
AUC ↔ 1,02 (0,97-1,07)
AUC ↔ 0.94 (0.85-1.04)
AUC ↔ 0,94 (0,85-1,04)
AUC ↔ 0.94 (0.88-1.01)
AUC ↔ 0,94 (0,88-1,01)
AUC ↔ 0.95 (0.64-1.42)
AUC ↔ 0,95 (0,64-1,42)
AUC ↔ 0.95 (0.90-0.99)
AUC ↔ 0,95 (0,90-0,99)
AUC ↔ 0.99 (0.79-1.25)
AUC ↔ 0,99 (0,79-1,25)
AUC ↔ 1.01 (0.93-1.10)
AUC ↔ 0,89 (0,82-0,96)
AUC ↔ 1.01 (0.93-1.10)
AUC ↔ 1,01 (0,93-1,10)
AUC ↔ 1.02 (0.97-1.07)
AUC ↔ 1,02 (0,97-1,07)
AUC ↔ 1.02 (0.97-1.07)
kombiniranog liječenja
AUC ↔ 1.03 (0.90-1.18)
AUC ↔ 1,06 (0,99-1,13)
AUC ↔ 1.03 (0.90-1.18)
AUC ↔ 1.03 (0,90-1,18)
AUC ↔ 1.06 (0.99-1.13)
AUC ↑ 1,27 (1,19-1,36)
AUC ↔ 1.06 (0.99-1.13)
AUC ↔ 1,06 (0,99-1,13)
AUC ↔ 1.06 (0.99-1.14)
AUC ↔ 1,06 (0,99-1,14)
AUC ↔ 1.10 (1.03-1.16)
AUC ↔ 1,10 (1,03-1,16)
AUC ↔ 1.10 (1.06-1.15)
AUC ↔ 1,10 (1,06-1,15)
AUC ↔ 1.10 (1.06-1.15)
izloženosti artemeteru i
AUC ↔ 1.11 (0.99-1.25)
AUC ↔ 1,11 (0,99-1,25)
AUC ↔ 1.15 (1.09-1.21)
AUC ↔ 1,15 (1,09-1,21)
AUC ↔a
Nije ispitivano.
AUC  35%
Raltegravir:
AUC(0- a, g.h/ml
AUC(0-)a, g.h/ml
AUC) of tacrolimus from Protopic is approximately 30-fold less than that seen with oral immunosuppressive doses in kidney and liver transplant patients.
AUC) takrolimusu iz Protopica približno je 30 puta manja od one opažene kod peroralnih imunosupresivnih doza u bolesnika s presađenim bubregom ili jetrom.
AUC) were observed with concurrent administration of a potent CYP3A4 inhibitor (ketoconazole 400 mg).
AUC) kad se istovremeno primjenjivao jaki inhibitor CYP3A4 (ketokonazol 400 mg).
AUC, Cmax, Cmin
(%) u AUC, Cmax, Cmin
AUC, Cmax, Cmin
lopinavirom/ritonavirom, doze
AUC/Dose (IU*h/dL per IU/kg)
AUC/Doza (IU*h/dl po IU/kg)
AUC0-12 μg•hr/mL
AUC0-12 μghr/mL
AUC0-12hr (μM●hr)
AUC 0-12h (μM●h)
AUC0-21days (µg.day/mL)
AUC0-21dan (µg.dan/ml)
AUC0-48 (h*IU/mL)
AUC0- 48 (h*IU/ml)
AUC0-48 hour ng/ml
AUC0-48 sat ng/ml
AUC0-72h (IU.hr/dL)a
AUC0-72h (IU.h/dl)a
AUC0-Day14 (mg•h/L)
AUC0-dan14 (mg•h/l)
AUC0-inf) for subjects with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment, respectively.
AUC0-inf) u ispitanika s blagim (Child-Pugh A), umjerenim (Child-Pugh B), odnosno teškim (Child-Pugh C) oštećenjem funkcije jetre.
AUC0-last (ng∙h/ml)
AUC0-posljednji (ng∙h/ml)
AUC0-t (ng∙hr/ml )
AUC0-t (ng*hr/ml)
AUC0-t, minute • µg/ml*
AUC0-t, minuta • µg/ml
AUC0-∞, h·μg/L
AUC0-∞, h·µg/l
AUC12 9.49 (7.94-11.34)
AUC12 9,49 (7,94-11,34)
AUC12 or 24
(mikrogram/ml) AUC12 ili 24
AUC12 or 24 (µgh/ml)
(mikrogram/ml) AUC12 ili 24
AUC12: ↓ 45 % (↓ 38 to ↓ 51)
AUC12: ↓ 45% (↓ 38 do ↓ 51)
AUC12: ↓ 45% (↓ 38 to ↓ 51)
AUC12: ↓ 45% (↓ 38 do ↓ 51)
AUC12: ↔ 0.98 Levonorgestrel.
Levonorgestrel AUC12:  0,98 Levonorgestrel.
AUC12h, h*ng /mL
AUC12h, h*ng/mL
AUC12h: ↓ 45% (↓ 38 to ↓ 51)
AUC12h: ↓ 45% (↓ 38 do ↓ 51)
AUC: +--
AUC: ↔
AUC: +--* (09 to j10)
AUC: ↔* (↓ 9 do ↑ 10)
AUC: 0 13%
AUC: ↓ 13
AUC: 0 17%
AUC: ↓ 17
AUC: 0 25% (0 16 to 0 32)b
AUC: ↓ 25% (↓ 16 do ↓ 32) b
AUC: 0 26% (0 15 to 0 36)
AUC: ↓ 26% (↓ 15 do ↓ 36)
AUC: 0 27% (0 20 to 0 33)
AUC: ↓ 27% (↓ 20 do ↓ 33)
AUC: 0 34% (0 21 to 0 41)
AUC: ↓ 34% (↓ 21 do ↓ 41)
AUC: 0 36% (0 32 to 0 40)
AUC: ↓ 36% (↓ 32 do ↓ 40)
AUC: 0 37% (0 14 to 0 55)
AUC: ↓ 37% (↓ 14 do ↓ 55)
AUC: 0 39% (0 21 to 0 53)
AUC: ↓ 39% (↓ 21 do ↓ 53)
AUC: 0 39% (0 27 to 0 50)
AUC: ↓ 39% (↓ 27 do ↓ 50)
AUC: 0 40% (0 26 to 0 57)
AUC: ↓ 40% (↓ 26 do ↓ 57)
AUC: 0 43% (0 34 to 0 50)
AUC: ↓ 43% (↓ 34 do ↓ 50)
AUC: 0 43% (0 7 to 0 65)
AUC: ↓ 43% (↓ 7 do ↓ 65)
AUC: 0 52% (0 33 to 0 66)
AUC: ↓ 52% (↓ 33 do ↓ 66)
AUC: 0 60% (0 52 to 0 68)
AUC: ↓ 60% (↓ 52 do ↓ 68)
AUC: 0 69% (0 55 to 0 79)
AUC: ↓ 69% (↓ 55 do ↓ 79)
AUC: 0 69% (0 62 to 0 73)
AUC: ↓ 69% (↓ 62 do ↓ 73)
AUC: 0 7% (0 23 to j 13) *
AUC: ↓ 7% (↓ 23 do ↑ 13)
AUC: 0 75% (0 59 to 0 84)
AUC: ↓ 75% (↓ 59 do ↓ 84)
AUC: 0 75% (0 62 to 0 84)
AUC: ↓ 75% (↓ 62 do ↓ 84)
AUC: 0 77%
AUC: ↓ 77
AUC: 0.98 (0.83, 1.15)
AUC: 0,98 (0,83, 1,15)
AUC: 071% (067 to 074)
Može se razmotriti
AUC: 1.03 (0.97, 1.09)
AUC: 1,03 (0,97; 1,09)
AUC: 1.05 (1.02, 1.08)
AUC: 1,05 (1,02; 1,08)
AUC: 1.33 (1.11, 1.59)
AUC: 1,33 (1,11, 1,59)
AUC: 1.41 (1.32, 1.50)
AUC:: 1,41 (1,32, 1,50)
AUC: j 11% (j 5 to j 18)
AUC: ↑ 11% (↑ 5 do ↑ 18)
AUC: j 17% (j 6 to j 29) **
AUC: ↑ 17% (↑ 6 do ↑ 29)
AUC: j 21%
AUC: ↑ 21
AUC: j 7% (j 1 to j 14)
AUC: ↑ 7% (↑ 1 do ↑ 14)
AUC: ↑ 1.4-fold Cmax: ↑ 1.3-fold
AUC: ↑ 1,4 puta Cmax: ↑ 1,3 puta
AUC: ↑ 1.5-fold Cmax: ↑ 1.5-fold Lapatinib:
AUC: ↑ 1,5 puta Cmax: ↑ 1,5 puta Lapatinib:
AUC: ↑ 1.5-fold of both enantiomers
AUC: ↑ 1,5 puta za oba enantiomera
AUC: ↑ 1.7-fold Cmax: ↑ 1.3-fold Cabozantinib AUC: ↑ 1.4-fold Cmax: ↔
Dabrafenib AUC: ↑ 1,7 puta Cmax: ↑ 1,3 puta Kabozantinib AUC: ↑ 1,4 puta Cmax: ↔
AUC: ↑ 1.8-fold
AUC: ↑ 1,8 puta
AUC: ↑ 1.9-fold Cmax: ↑ 1.7-fold Dasatinib
AUC: ↑ 1,9 puta Cmax: ↑ 1,7 puta Dasatinib
AUC: ↑ 11 % (↑ 5 to ↑ 18)
AUC: ↑ 11% (↑ 5 do ↑ 18)
AUC: ↑ 11% (↑ 5 to ↑ 18)
AUC: ↑ 11% (↑ 5 do ↑ 18)
AUC: ↑ 13-fold
Avanafil: AUC: ↑ 13 puta
AUC: ↑ 13-fold
primjene s
AUC: ↑ 153%
Rivaroksaban: AUC: ↑ 153
AUC: ↑ 17 % (↑ 6 to ↑ 29) **
AUC: ↑ 17% (↑ 6 do ↑ 29)
AUC: ↑ 2 fold Cmax: ↑ 2 fold
Cinakalcet AUC: ↑ 2 puta
AUC: ↑ 2-fold Cmax: ↑ 5-fold
Sildenafil: AUC: ↑ 11 puta
AUC: ↑ 2.4-fold
AUC: ↑ 3 puta
AUC: ↑ 2.4-fold
Trazodon: AUC: ↑ 2,4 puta
AUC: ↑ 20 % (↑ 8 to ↑ 34)
AUC: ↑ 20% (↑ 8 do ↑ 34)
AUC: ↑ 20% (↑ 8 to ↑ 34)
AUC: ↑ 20% (↑ 8 do ↑ 34)
AUC: ↑ 21 % (↑ 10 to ↑ 34)
AUC: ↑ 21% (↑ 10 do ↑ 34)
AUC: ↑ 21 % (↑ 10 to ↑ 34)
C12: ↓ 21
AUC: ↑ 21%
na dan)
AUC: ↑ 21% (↑ 10 to ↑ 34)
AUC: ↑ 21% (↑ 10 do ↑ 34)
AUC: ↑ 26% (↑ 20 to ↑ 32)
AUC: ↑ 26% (od ↑ 20 do ↑ 32)
AUC: ↑ 3.0 to 3.9-fold
AUC: ↑ 3,0 - 3,9 puta
AUC: ↑ 3.0-fold Erlotinib:
AUC: ↑ 3,0 puta Erlotinib:
AUC: ↑ 3.6-fold Nilotinib:
AUC: ↑ 3,6 puta Nilotinib:
AUC: ↑ 32% (↑ 25 to ↑ 38)
AUC: ↑ 32% (↑ 25 do ↑ 38)
AUC: ↑ 34 % (↑ 18 to ↑ 53)
AUC: ↑ 34% (↑ 18 do ↑ 53)
AUC: ↑ 4% (↓ 3 to ↑ 11)
AUC: ↑ 4% (od ↓ 3 do ↑ 11)
AUC: ↑ 4% (↓ 3 – ↑ 11)
AUC: ↓ 4% (↓ 32 – ↑ 34)
AUC: ↑ 5% (↓ 2 to ↑ 13)
AUC: ↑ 5% (od ↓ 2 do ↑ 13)
AUC: ↑ 5% (↓ 2 – ↑ 13)
AUC: ↓ 12% (↓ 16 – ↓ 8)
AUC: ↑ 5-fold
AUC: ↑ 5 puta
AUC: ↑ 5-fold
AUC: ↑ 7,2 puta
AUC: ↑ 5.7-fold Cmax: ↑ 3.5-fold
AUC: ↑ 3 puta
AUC: ↑ 6% (↓ 1 – ↑ 13)
AUC: ↓ 7% (↓ 13 – ↓ 1)
AUC: ↑ 6% (↓ 1 – ↑ 13)
Cmax: ↓ 6% (↓ 13 – ↑ 0)
AUC: ↑ 7 % (↑ 1 to ↑ 14)
AUC: ↑ 7% (↑ 1 do ↑ 14)
AUC: ↑ 7% (↑ 1 to ↑ 14)
AUC: ↑ 7% (↑ 1 do ↑ 14)
AUC: ↑ 7.2-fold
AUC: ↑ 7,2 puta
AUC: ↑ 96% (↑ 74 to ↑ 121)
AUC: ↑ 96% (od ↑ 74 do ↑ 121)
AUC: ↑ 98% (↑ 77 to ↑ 123)
AUC: ↑ 98% (od ↑ 77 do ↑ 123)
AUC: ↑ have been observed Cmax: ↑ have been observed
AUC: Primijećeno je ↑ Cmax: Primijećeno je ↑
AUC: ↑40% (↑ 31 – ↑ 50)
AUC: ↑98% (↑ 77 – ↑ 123)
AUC: ↓ 1% (↓ 8 to ↑ 6)
AUC: ↓ 1% (od ↓ 8 do ↑ 6)
AUC: ↓ 11% (↓ 14 to ↓ 7)
AUC: ↓ 11% (od ↓ 14 do ↓ 7)
AUC: ↓ 12% (↓ 16 to ↓ 8)
AUC: ↓ 12% (od ↓ 16 do ↓ 8)
AUC: ↓ 18% (↓ 10 to ↓ 26)
AUC: ↓ 18% (↓ 10 do ↓ 26)
AUC: ↓ 18% (↓ 8 to ↓ 27)
AUC: ↓ 18% (↓ 8 do ↓ 27)
AUC: ↓ 2% (↓ 5 to ↑ 0)
AUC: ↓ 2% (od ↓ 5 do ↑ 0)
AUC: ↓ 21%
AUC: ↓ 43% (↓ 7 do ↓ 65)
AUC: ↓ 25% (↓ 16 to ↓32) b
AUC: ↓ 25% (↓ 16 do ↓32) b
AUC: ↓ 25% (↓ 42 to ↓ 3)
AUC: ↓ 25% (↓ 42 do ↓ 3)
AUC: ↓ 26 % (↓ 15 to ↓ 36)
AUC: ↓ 26% (↓ 15 do ↓ 36)
AUC: ↓ 26% (↓ 15 to ↓ 36)
AUC: ↓ 26% (↓ 15 do ↓ 36)
AUC: ↓ 27 % (↓ 20 to ↓ 33)
AUC: ↓ 27% (↓ 20 do ↓ 33)
AUC: ↓ 27 % (↓ 20 to ↓ 33)
AUC: ↓ 39% (↓ 27 do ↓ 50)
AUC: ↓ 27% (↓ 20 to ↓ 33)
AUC: ↓ 27% (↓ 20 do ↓ 33)
AUC: ↓ 27% (↓ 35 to ↓ 18)
AUC: ↓ 27% (od ↓ 35 do ↓ 18)
AUC: ↓ 3% (↓ 8% to ↑ 15)
AUC: ↓ 3% (od ↓ 8% do ↑ 15)
AUC: ↓ 31 % (↓ 8 to ↓ 47)
AUC: ↓ 31% (↓ 8 do ↓ 47)
AUC: ↓ 31% (↓ 8 to ↓ 47)
AUC: ↓ 31% (↓ 8 do ↓ 47)
AUC: ↓ 31% (↓ 8 to ↓47)
AUC: ↓ 31% (↓ 8 do ↓47)
AUC: ↓ 34 % (↓ 21 to ↓ 41)
AUC: ↓ 34% (↓ 21 do ↓ 41)
AUC: ↓ 34% (↓ 21 to ↓ 41)
AUC: ↓ 34% (↓ 21 do ↓ 41)
AUC: ↓ 34% (↓ 41 to ↓ 25)
AUC: ↓ 34% (od ↓ 41 do ↓ 25)
AUC: ↓ 35 % (↓ 13 to ↓ 40)
AUC: ↓ 35% (↓ 13 do ↓ 40)
AUC: ↓ 35%
Etravirin: AUC: ↓ 35
AUC: ↓ 35% (↓ 13 to ↓ 40)
AUC: ↓ 35% (↓ 13 do ↓ 40)
AUC: ↓ 36 %
Cmax: ↓ 14 % (↓ 3 do ↓ 24)
AUC: ↓ 36 % (↓ 32 to ↓ 40)
AUC: ↓ 36% (↓ 32 do ↓ 40)
AUC: ↓ 36% (↓ 32 to ↓ 40)
AUC: ↓ 36% (↓ 32 do ↓ 40)
AUC: ↓ 37 % (↓ 14 to ↓ 55)
AUC: ↓ 37% (↓ 14 do ↓ 55)
AUC: ↓ 37% (↓ 14 to ↓ 55)
AUC: ↓ 37% (↓ 14 do ↓ 55)
AUC: ↓ 38 % (↓ 28 to ↓ 47)
AUC: ↓ 38% (↓ 28 do ↓ 47)
AUC: ↓ 38% (↓ 28 to ↓ 47)
AUC: ↓ 38% (↓ 28 do ↓ 47)
AUC: ↓ 39 % (↓ 21 to ↓ 53)
AUC: ↓ 39% (↓ 21 do ↓ 53)
AUC: ↓ 39 % (↓ 27 to ↓ 50)
AUC: ↓ 39% (↓ 27 do ↓ 50)
AUC: ↓ 39 % (↓ 27 to ↓ 50)
AUC: ↓ 55% (↓ 48 do ↓ 62)
AUC: ↓ 39 % (↓ 30 to ↓ 46)
AUC: ↓ 39% (↓ 30 do ↓ 46)
AUC: ↓ 39% (↓ 21 to ↓ 53)
AUC: ↓ 39% (↓ 21 do ↓ 53)
AUC: ↓ 39% (↓ 27 to ↓ 50)
AUC: ↓ 39% (↓ 27 do ↓ 50)
AUC: ↓ 39% (↓ 30 to ↓ 46)
AUC: ↓ 39% (↓ 30 do ↓ 46)
AUC: ↓ 4% (↓ 15 to ↑ 8)
AUC: ↓ 4% (od ↓ 15 do ↑ 8)
AUC: ↓ 4% (↓ 32 to ↑ 34)
AUC: ↓ 4% (od ↓ 32 do ↑ 34)
AUC: ↓ 4% (↓ 32 – ↑ 34)
AUC: ↑ 26% (↑ 20 – ↑ 32)
AUC: ↓ 4% (↓ 7 to ↓ 1)
AUC: ↓ 4% (od ↓ 7 do ↓ 1)
AUC: ↓ 40 % (↓ 26 to ↓ 57)
AUC: ↓ 40% (↓ 26 do ↓ 57)
AUC: ↓ 40 % (↓ 26 to ↓ 57)
Uz hormonske kontraceptive
AUC: ↓ 40% (↓ 26 to ↓ 57)
AUC: ↓ 40% (↓ 26 do ↓ 57)
AUC: ↓ 43 % (↓ 34 to ↓ 50)
AUC: ↓ 43% (↓ 34 do ↓ 50)
AUC: ↓ 43% (↓ 34 to ↓ 50)
AUC: ↓ 43% (↓ 34 do ↓ 50)
AUC: ↓ 43% (↓ 7 to ↓ 65)
AUC: ↓ 43% (↓ 7 do ↓ 65)
AUC: ↓ 46%
AUC: ↓ 75% (↓ 62 do ↓ 84)
AUC: ↓ 5% (↓ 9 to ↓ 1)
AUC: ↓ 5% (od ↓ 9 do ↓ 1)
AUC: ↓ 50 %
AUC: ↓ 52% (↓ 33 do ↓ 66)
AUC: ↓ 50%
Cmax: ↓ 46
AUC: ↓ 50%
dozi
AUC: ↓ 52 % (↓ 33 to ↓ 66)
AUC: ↓ 52% (↓ 33 do ↓ 66)
AUC: ↓ 52% (↓ 33 to ↓ 66)
AUC: ↓ 52% (↓ 33 do ↓ 66)
AUC: ↓ 55% (↓ 48 to ↓ 62)
AUC: ↓ 55% (↓ 48 do ↓ 62)
AUC: ↓ 55% (↓ 48 to ↓ 62)
AUC: ↓ 69% (↓ 55 do ↓ 79)
AUC: ↓ 58 % (↓ 39 to ↓ 68)
AUC: ↓ 58% (↓ 39 do ↓ 68)
AUC: ↓ 58 % (↓ 39 to ↓ 68)
Cmax: ↓ 46% (↓ 39 do ↓ 52)
AUC: ↓ 58% (↓ 39 to ↓ 68)
AUC: ↓ 58% (↓ 39 do ↓ 68)
AUC: ↓ 60 % (↓ 52 to ↓ 68)
AUC: ↓ 60% (↓ 52 do ↓ 68)
AUC: ↓ 60% (↓ 52 to ↓ 68)
AUC: ↓ 60% (↓ 52 do ↓ 68)
AUC: ↓ 69 % (↓ 55 to ↓ 79)
AUC: ↓ 69% (↓ 55 do ↓ 79)
AUC: ↓ 69 % (↓ 62 to ↓ 73)
AUC: ↓ 64% (↓ 62 do ↓ 67)
AUC: ↓ 69 % (↓ 62 to ↓ 73)
AUC: ↓ 69% (↓ 62 do ↓ 73)
AUC: ↓ 69% (↓ 55 to ↓ 79)
AUC: ↓ 69% (↓ 55 do ↓ 79)
AUC: ↓ 69% (↓ 62 to ↓ 73)
AUC: ↓ 69% (↓ 62 do ↓ 73)
AUC: ↓ 7 % (↓ 23 to ↑ 13) *
AUC: ↓ 7% (↓ 23 do ↑ 13)
AUC: ↓ 7% (↓ 13 to ↓ 1)
AUC: ↓ 7% (od ↓ 13 do ↓ 1)
AUC: ↓ 7% (↓ 23 to ↑ 13) *
AUC: ↓ 7% (↓ 23 do ↑ 13)
AUC: ↓ 71% (↓ 67 to ↓ 74)
AUC: ↓ 71% (↓ 67 do ↓ 74)
AUC: ↓ 75 % (↓ 59 to ↓ 84)
AUC: ↓ 35% (↓ 13 do ↓ 40)
AUC: ↓ 75 % (↓ 59 to ↓ 84)
AUC: ↓ 75% (↓ 59 do ↓ 84)
AUC: ↓ 75% (↓ 59 to ↓ 84)
AUC: ↓ 75% (↓ 59 do ↓ 84)
AUC: ↓ 75% (↓ 62 to ↓ 84)
AUC: ↓ 75% (↓ 62 do ↓ 84)
AUC: ↓ 9% (↓ 16 to ↓ 1)
AUC: ↓ 9% (od ↓ 16 do ↓ 1)
AUC: ↓ 9% (↓ 16 – ↓ 1)
Cmax: ↓ 23% (↓ 30 – ↑ 16)
AUC: ↓71% (↓67 to ↓74)
AUC: ↓ 71% (↓ 67 do ↓ 74)
AUC: ↔
elvitegravirom.
AUC: ↔
Kobicistat: AUC: ↔
AUC: ↔ 1.18
AUC:  1,18 Midazolam.
AUC: ↔ 1.18
Benzodiazepini
AUC: ↔* (↓ 9 to ↑ 10)
AUC: ↔* (↓ 9 do ↑ 10)
AUC: ↔**
Atazanavir: AUC: ↔
AUC: ↔*/** (↓ 10 to ↑ 26) Cmax: ↔*/** (↓ 5 to ↑ 26) Cmin: ↑ 12%*/** (↓ 16 to ↑ 49) (CYP3A4 induction)
Cmax: ↔*/** (↓ 5 do ↑ 26) Cmin: ↑ 12%*/** (↓ 16 do ↑ 49) (indukcija CYP3A4)
AUC: ↔*/** (↓ 10% to ↑ 26%) Cmax: ↔*/** (↓ 5% to ↑ 26%) Cmin: ↑ 12%*/** (↓ 16 to ↑ 49) (CYP3A4 induction).
AUC: ↔*/** (↓ 10% do ↑ 26%) Cmax: ↔*/** (↓ 5% do ↑ 26%) Cmin: ↑ 12%*/** (↓ 16 do ↑ 49) (indukcija CYP3A4).
AUC:↑22%
doza
AUC:↑30%
lopinavirom/ritonavirom.
AUC= area under the plasma concentration curve (extrapolated to infinity for ONIVYDE and AUC24h for non-liposomal irinotecan)
AUC= površina ispod krivulje koncentracije u plazmi (ekstrapolirano do beskonačnosti za ONIVYDE i AUC24h za neliposomalni irinotekan)
AUCGIR,2-24h: metabolic effect in last 22 hours of dosing interval (i.e., not influenced by i.v. insulin during the clamp run-in period).
AUCGIR,2-24h: metabolički učinak u posljednja 22 sata intervala doziranja (odnosno, bez utjecaja intravenskog inzulina tijekom početnog razdoblja ispitivanja pomoću clamp metode)
AUCinf = area under the plasma concentration-time profiles extrapolated to infinity; AUCtau = area under the plasma concentration-time profiles during the 24 h interval at steady state; Cmax = peak plasma concentration; Cmin,ss = trough levels at steady state.
AUCinf = površina ispod krivulje koncentracija u plazmi -vrijeme ekstrapolirano u beskonačnost; AUCtau = površina ispod krivulje koncentracija u plazmi -vrijeme tijekom intervala od 24 sata u stanju dinamičke ravnoteţe; Cmax = vršna koncentracija u plazmi; Cmin,ss = najniţe razine u stanju dinamičke ravnoteţe.
AUCinf: ↑ 18%
Dekstrometorfan: AUCinf: ↑ 18
AUCinf: ↑ 20%
R-varfarin AUCinf: ↑ 20
AUCinf: ↓ 10%
AUCinf: ↑ 10
AUCs of total ertapenem and of unbound ertapenem are increased in patients with moderate renal impairment (Clcr 31 to
AUC ukupnog ertapenema u bolesnika s umjerenim oštećenjem funkcije bubrega (Clcr 31 do
AUCss (ng∙hr/mL)
AUCss (ng/h/ml)
AUCss (nghr/mL)
(ngh/ml)
AUCss, 0-21days (µg.day/mL)
AUCss0-21dan (µg.dan/ml)
AUCtau (μg·h/ml)
AUCtau (μg h/ml)
AUCτ, ss (ng.h/mL)
AUCτ ss (ng.h/ml)
AUCτ,ss (ng.h/mL)
AUC τ, ss (ng.h/ml)
AUCτ,ss decreased by 16 % for a 45-year old patient (5th percentile) and increased by 13 % for a 76-year old patient (95th percentile) relative to a patient with the median age of 62 years.
AUCτ,ss se smanjio za 16 % u 45-godišnjeg bolesnika (5. percentila), a povećao za 13 % u 76-godišnjeg bolesnika (95. percentila) u odnosu na bolesnika s medijanom dobi od 62 godine.
AUCτ,ss increased by 25 % for a 50 kg patient (5th percentile) and decreased by 19 % for a 100 kg patient (95th percentile) relative to a patient with the median weight of 71.5 kg.
AUCτ,ss se povećao za 25 % u bolesnika s 50 kg (5. percentil), a smanjio za 19 % u bolesnika sa 100 kg (95. percentil) u odnosu na bolesnike s medijanom težine od 71,5 kg.
AUCτ,ss increased by 25% for a 50 kg patient (5th percentile) and decreased by 19% for a 100 kg patient (95th percentile) relative to a patient with the median weight of 71.5 kg.
AUCτ,ss se povećao za 25% u bolesnika s 50 kg (5. percentila), a smanjio za 19% u bolesnika sa 100 kg (95. percentila) u odnosu na bolesnika s medijanom težine od 71,5 kg.
AUC↓ 0.75 (0.69-0.81)
AUC↓ 0,75 (0,69-0,81)
AUC↔ 1.11(1.02-1.20)
AUC↔ 1,11(1,02-1,20)
AUC (gh/ml)
AUC (µgh/ml)
Auditory and ophthalmic testing
Ispitivanje sluha i vida
auditory canal
lušnog kanala
Augmentation refers to the earlier onset of symptoms in the evening (or even afternoon), increase in symptoms, and spread of symptoms to involve other extremities.
Augmentacija se odnosi na raniji nastup večernjih simptoma (ili čak poslijepodne), povećanje simptoma i širenje simptoma na druge ekstremitete.
Augmentation.
Augmentacija (povećanje simptoma).
Augmentation.
Augmentacija.
AURA (Phase I) was an open-label, single arm dose-escalation and expansion Phase I trial including 271 pre-treated patients with locally advanced or metastatic NSCLC across multiple dose expansion cohorts.
AURA (faza I) je bilo otvoreno ispitivanje faze I s jednom skupinom i eskalacijom i ekspanzijom doze, u koje je bilo uključeno 271 prethodno liječenih bolesnika s lokalno uznapredovalim ili metastatskim NSCLC-om, u više kohorti za ekspanziju doze.
AURA (PhI
(Ekspanzija faze I)
AURAex (Phase II)
AURAex (Faza II)
Auricular administration of five times the recommended dose, one week apart, for 5 consecutive weeks (a total six administrations of 5 tubes per ear or 10 tubes per dog) to mixed breed dogs weighing 10 to 14 kg resulted in clinical signs of wetness of the inner and outer pinna (attributed to presence of the product).
Aurikularna primjena doza pet puta većih od preporučenih, u razmaku od tjedan dana, tijekom pet uzastopnih tjedana (ukupno šest primjena 5 tuba po uhu ili 10 tuba po psu) psima mješancima koji teže od 10 do 14 kg rezultirala je kliničkim znakovima; vlažnost unutarnje i vanjske uške (pripisano prisutnosti proizvoda).
auricular swelling, ear pain
oticanje ušne školjke, bol u uhu
Auricular use
Aurikularna primjena.
Auricular use.
Aurikularna primjena.
Aurovitas Spain, S.A.U. Tfno.: +34 91 630 86 45
Actavis Spain, S.A. Tfno.: +34 91 630 86 45
Aurovitas Spain, S.A.U.Tfno.: +34 91 630 86 45
Actavis Spain, S.A. Tfno.: +34 91 630 86 45
Aurovitas, Unipessoal, Lda Tel: +351 214 185 104
Actavis A/S Sucursal Tel: + 351 21 722 06 50
Austria
A-4020 Linz Austrija
Austria
Poljska
Austria/ Österreich
Austrija/Österreich
Authorised Representative in the EEA for Comar Plastics: MDSS, Burckhardstrasse 1, 30163 Hannover, Germany
Predstavnik nositelja odobrenja u EEA za Comar Plastics: MDSS, Burckhardstrasse 1, 30163 Hannover, Njemačka
Autoantibody formation
Stvaranje autoprotutijela
AutoClicks pre-filled pen is designed to work accurately and safely.
Napunjena brizgalica (AutoClicks) dizajnirana je tako da radi točno i sigurno.
Autoimmune conditions
Autoimune bolesti
autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection.
autoimuni poremećaji (stanje koje se javlja kada imunološki sustav napada zdravo tkivo u tijelu) mogu se javiti nakon što počnete uzimati lijekove za liječenje HIV infekcije.
Autoimmune disorders (such as Graves' disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.8).
Pojava autoimunih poremećaja (poput Gravesove bolesti) također je bila prijavljena prilikom imunološke reaktivacije; međutim, prijavljeno vrijeme do nastanka je jako varijabilno, te ovi događaji mogu nastati puno mjeseci nakon početka liječenja (vidjeti dio 4.8).
Autoimmune disorders (such as Graves' disease) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Autoimune bolesti (kao što je Gravesova bolest) su također bile prijavljene; međutim, vrijeme prijave pojave tih bolesti je vrlo varijabilno jer se mogu dogoditi i više mjeseci nakon početka liječenja. (vidjeti dio 4.4).
Autoimmune disorders (such as Graves' disease) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Pojava autoimunih poremećaja (poput Gravesove bolesti) također je bila prijavljena; međutim, prijavljeno vrijeme do nastanka je jako varijabilno, te ovi događaji mogu nastati puno mjeseci nakon početka liječenja (vidjeti dio 4.4).
Autoimmune disorders (such as Graves' disease) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Prijavljene su i autoimune bolesti (kao što je Gravesova bolest); međutim, prijavljeno vrijeme do nastupa vrlo je varijabilno jer se ti događaji mogu javiti i više mjeseci nakon početka liječenja (vidjeti dio 4.4).
Autoimmune disorders (such as Graves’ disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and can occur many months after initiation of treatment.
U uvjetima imunološke reaktivacije prijavljeni su i autoimuni poremećaji (poput Gravesove bolesti); međutim, prijavljeno vrijeme do nastupa bolesti je varijabilno pa se ona može javiti i mjesecima nakon uvođenja liječenja.